MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 15 - Thomas Biegi News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thomas Biegi Today - Breaking & Trending Today
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys AG / Key word(s): Agreement MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felza...
Source: businessinsider.com
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests
Source: finanznachrichten.de
MorphoSys AG Reports Outcome of Annual General Meeting 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company's Management and Supervisory
Source: finanznachrichten.de
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG / Key word(s): AGM/EGM MorphoSys AG Reports Outcome of Annual General Meeting 2022 18.05.2022 / 22:02 ...
Source: businessinsider.com